Explain The Role MHC Class II Plays On The Immune System?
The role MHC class II plays on the immune system is that some of its genes code for proteins that will be expressed on the surface of the immune system cells. Peptides which are protein fragments outside the cells will allow these proteins to be attached to them, if these proteins are recognised by the immune system as foreign (such as viral and bacterial) the MHC will send a signal to the immune system to trigger an immune response against the invading bacteria or virus.
The HLA class I and class II proteins play a role in the adaptive immune system. These proteins will present peptides on the cell surface so they call be recognised by the T-cells. MHC class I peptides will be expressed on nucleated cells and will be recognised bt the cytotoxic …show more content…
Statistics have shown that AML is the most common acute leukaemia that will affect adults and as the older people are at more risk of being diagnosed with AML than the younger people. AML is characterized by an increased proliferation of megakaryocytes, monocytes, granulocytes, and erythrocytes (Auclerc, et.al. 2004; 374, Dohner&Estey, 2006:1894). The replacement or normal bone marrow with blasts will induce the symptoms of AML and this replacement of the bone marrow with blasts will cause a pancytopenia (a decrease in all cell lines).The symptoms that may be seen in AML include fatigue, shortness of breath, easy bruising and bleeding, and increased risk of …show more content…
2002). When using the FAB classification acute myeloid leukaemia was divided into subtypes from M0 through to M7 and this was all based on morphological and cytochemical findings (Bennett et al., 1976). This WHO classification system (WHO, 1999) further expended the parameters used when diagnosing AML they based their classification on the immunological, cytogenetic, morphological and clinical findings (Moe et al., 2008). The revised (2008) World Health Organization classification system develops and improves the FAB system. According to the WHO classification, acute myeloid leukaemias are grouped into four categories: (i) AML with recurrent genetic abnormalities; (ii) AML with multilineage dysplasia; (iii) therapy-related disorders; therapy-related AML and therapy-related myelodysplastic syndromes; and (iv) AML not otherwise categorized (Betz and Hess et al.,
The HLA class I and class II proteins play a role in the adaptive immune system. These proteins will present peptides on the cell surface so they call be recognised by the T-cells. MHC class I peptides will be expressed on nucleated cells and will be recognised bt the cytotoxic …show more content…
Statistics have shown that AML is the most common acute leukaemia that will affect adults and as the older people are at more risk of being diagnosed with AML than the younger people. AML is characterized by an increased proliferation of megakaryocytes, monocytes, granulocytes, and erythrocytes (Auclerc, et.al. 2004; 374, Dohner&Estey, 2006:1894). The replacement or normal bone marrow with blasts will induce the symptoms of AML and this replacement of the bone marrow with blasts will cause a pancytopenia (a decrease in all cell lines).The symptoms that may be seen in AML include fatigue, shortness of breath, easy bruising and bleeding, and increased risk of …show more content…
2002). When using the FAB classification acute myeloid leukaemia was divided into subtypes from M0 through to M7 and this was all based on morphological and cytochemical findings (Bennett et al., 1976). This WHO classification system (WHO, 1999) further expended the parameters used when diagnosing AML they based their classification on the immunological, cytogenetic, morphological and clinical findings (Moe et al., 2008). The revised (2008) World Health Organization classification system develops and improves the FAB system. According to the WHO classification, acute myeloid leukaemias are grouped into four categories: (i) AML with recurrent genetic abnormalities; (ii) AML with multilineage dysplasia; (iii) therapy-related disorders; therapy-related AML and therapy-related myelodysplastic syndromes; and (iv) AML not otherwise categorized (Betz and Hess et al.,